EVOMMUNE INC

Arthur Kirsch’s patient 10,000‑share build in EVOMMUNE signals insider confidence amid a weak week—use this insight to gauge long‑term value.

EVOMMUNE insider option buys signal executive confidence, hinting at future dilution and upcoming clinical milestones.

Insider buying surge at Evommune signals confidence in its biotech pipeline and bullish prospects—ideal for investors tracking clinical milestones.

RA Capital’s $27.88 buy of Evommune shares signals confidence that the $125 M private placement will boost clinical progress and stabilize the stock price, offering investors a potential catalyst for growth.